Equity Overview
Price & Market Data
Price: $0.665
Daily Change: -$0.0373 / 5.60%
Daily Range: $0.641 - $0.706
Market Cap: $47,261,592
Daily Volume: 42,700
Performance Metrics
1 Week: -8.13%
1 Month: -29.90%
3 Months: -10.26%
6 Months: -44.09%
1 Year: -49.97%
YTD: -25.94%
Details
Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada. It focuses on developing its lead drug candidate LSALT Peptide, which is in Phase 2 trials to treat inflammation related acute kidney injury experienced by patients undergoing on-pump (bypass) cardiac surgery; and cilastatin to prevent toxin related acute kidney injury via dipeptidase-1. The company also develops CKD Platform, therapeutics targeting chronic kidney disease. Arch Biopartners Inc. is based in Toronto, Canada.